BRPI0919292A2 - 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios - Google Patents

3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios

Info

Publication number: BRPI0919292A2
Authority: BR; Brazil
Prior art keywords: carboxamides; imidazo; pyridine; inflammatory agents; inflammatory
Prior art date: 2008-09-25

Application number

BRPI0919292A

Other languages

English (en)

Inventor

Doods Henri

Arndt Kirsten

Klinder Klaus

Hauel Norbert

Kuelzer Raimund

Pfau Roland

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-25

Filing date

2009-09-25

Publication date

2017-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919292(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-25 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2017-05-30 Publication of BRPI0919292A2 publication Critical patent/BRPI0919292A2/pt

Links

ARIWQDYLRYFPTP-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyridine-6-carboxamide Chemical class NC(=O)C1=CN=C2N=CNC2=C1 ARIWQDYLRYFPTP-UHFFFAOYSA-N 0.000 title 1
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)

BRPI0919292A 2008-09-25 2009-09-25 3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios BRPI0919292A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9998708P	2008-09-25	2008-09-25
EP08165120		2008-09-25
PCT/EP2009/062425 WO2010034799A1 (en)	2008-09-25	2009-09-25	3h-imidaz0 [4, 5-b] pyridine- 6 -carboxamides as anti -inflammatory agents

Publications (1)

Publication Number	Publication Date
BRPI0919292A2 true BRPI0919292A2 (pt)	2017-05-30

Family

ID=40344110

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0919292A BRPI0919292A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI0919295A BRPI0919295A2 (pt)	2008-09-25	2009-09-25	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
BRPI0919295A BRPI0919295A2 (pt)	2008-09-25	2009-09-25	1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0919738A BRPI0919738A2 (pt)	2008-09-25	2009-09-25	3h-imidazo[4,5-c] piridino-6-carboxamidas como agentes anti-inflamatórios

Country Status (17)

Country	Link
US (4)	US8703796B2 (pt)
EP (4)	EP2334652A1 (pt)
JP (4)	JP5591807B2 (pt)
KR (4)	KR20110056530A (pt)
CN (4)	CN102224143A (pt)
AR (4)	AR073684A1 (pt)
AU (4)	AU2009295814A1 (pt)
BR (3)	BRPI0919292A2 (pt)
CA (4)	CA2737384A1 (pt)
IL (4)	IL211137A0 (pt)
MX (4)	MX2011003094A (pt)
NZ (4)	NZ591846A (pt)
RU (4)	RU2011116129A (pt)
TW (4)	TW201016682A (pt)
UY (1)	UY32138A (pt)
WO (4)	WO2010034799A1 (pt)
ZA (2)	ZA201101041B (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100250458A1 (en) *	2009-03-30	2010-09-30	Mspot, Inc.	Content based social networking system and method
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US8394969B2 (en) *	2008-09-26	2013-03-12	Merck Sharp & Dohme Corp.	Cyclic benzimidazole derivatives useful as anti-diabetic agents
UY32470A (es) *	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
NZ596538A (en)	2009-05-12	2014-04-30	Romark Lab Lc	Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh)	2009-06-26	2018-05-18	罗马克实验室有限公司	用于治疗流感的化合物和方法
WO2011099832A2 (en) *	2010-02-12	2011-08-18	Crystalgenomics, Inc.	Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) *	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
TW201305178A (zh)	2010-10-29	2013-02-01	Glenmark Pharmaceuticals Sa	作為ｍＰＧＥＳ－１抑制物的三環化合物
US8486968B2 (en) *	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds
UY33779A (es) *	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
AR084174A1 (es)	2010-12-21	2013-04-24	Lilly Co Eli	Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
WO2012102937A2 (en) *	2011-01-25	2012-08-02	Irm Llc	Compounds that expand hematopoietic stem cells
SG192941A1 (en) *	2011-02-25	2013-09-30	Merck Sharp & Dohme	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2495244A1 (en)	2011-03-02	2012-09-05	NovaSaid AB	Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
WO2013012848A1 (en)	2011-07-18	2013-01-24	Merck Patent Gmbh	Benzamides
WO2013038308A1 (en)	2011-09-15	2013-03-21	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
WO2013072825A1 (en)	2011-11-16	2013-05-23	Glenmark Pharmaceuticals S.A.	Phtalazinone derivatives as mpegs -1 inhibitors
AR089939A1 (es)	2012-02-09	2014-10-01	Glenmark Pharmaceuticals Sa	COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
WO2013153535A1 (en)	2012-04-13	2013-10-17	Glenmark Pharmaceuticals S.A.	TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CN103450329B (zh) *	2012-05-29	2015-05-27	首都医科大学	3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用
BR112014030940B1 (pt)	2012-06-11	2022-09-06	UCB Biopharma SRL	Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CN103922999B (zh) *	2013-01-16	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法及中间体化合物
US20140221335A1 (en) *	2013-02-06	2014-08-07	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104030977B (zh) *	2013-03-07	2016-05-04	上海医药工业研究院	一种达比加群酯中间体的制备方法
WO2014167444A1 (en)	2013-04-08	2014-10-16	Glenmark Pharmaceuticals S.A.	SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
WO2014209841A2 (en) *	2013-06-25	2014-12-31	F. Hoffmann-La Roche Ag	Compounds for treating spinal muscular atrophy
CN103435554A (zh) *	2013-09-06	2013-12-11	中国药科大学	2-苯氨基苯并咪唑类化合物及其用途
WO2015059618A1 (en)	2013-10-22	2015-04-30	Glenmark Pharmaceuticals S.A.	SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
US9951027B2 (en)	2014-02-11	2018-04-24	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as MIDH1 inhibitors
EA031655B1 (ru)	2014-02-11	2019-02-28	Байер Фарма Акциенгезельшафт	Бензимидазол-2-амины в качестве ингибиторов midhi
WO2015166398A1 (en) *	2014-04-30	2015-11-05	Aurigene Discovery Technologies Limited	3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors
CN105198959B (zh) *	2014-06-13	2018-09-07	首都医科大学	咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用
CN105198960B (zh) *	2014-06-13	2018-10-19	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105294829B (zh) *	2014-06-13	2018-07-27	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用
CN105254709A (zh) *	2014-07-10	2016-01-20	首都医科大学	咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105315325A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用
CN105315335A (zh) *	2014-07-10	2016-02-10	首都医科大学	咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用
WO2016016861A1 (en)	2014-08-01	2016-02-04	Glenmark Pharmaceuticals S.A.	Nanoparticulate formulation comprising a mpges-1 inhibitor
JP6645695B2 (ja) *	2014-10-14	2020-02-14	中尾　洋一	イミダゾピリジンアミン化合物、その製造方法及び用途
JP6672288B2 (ja)	2014-10-23	2020-03-25	バイエル・ファルマ・アクティエンゲゼルシャフト	腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール
WO2016062677A1 (en) *	2014-10-23	2016-04-28	Bayer Pharma Aktiengesellschaft	Benzimidazol-2-amines as midh1 inhibitors
CN106146615B (zh) *	2015-03-23	2021-08-24	首都医科大学	咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性和应用
KR20180005250A (ko)	2015-05-21	2018-01-15	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Pad4 억제제로서의 벤조이미다졸 유도체
EP3303302B1 (en)	2015-06-08	2019-03-20	Bayer Pharma Aktiengesellschaft	N-menthylbenzimidazoles as midh1 inhibitors
CN107698660B (zh) *	2015-06-23	2021-06-08	首都医科大学	咪唑并吡啶-6-甲酰-Lys(Lys)-寡肽,其合成,活性和应用
JP6824954B2 (ja)	2015-07-16	2021-02-03	ドイチェスクレープスフォルシュングスツェントルムシュティフトゥングデスエッフェントリッヒェンレヒツ	ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール
EP3390387B1 (en)	2015-12-18	2021-11-17	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
SG11202003743SA (en)	2017-11-22	2020-06-29	Khondrion Ip B V	Compounds as mpges-1 inhibitors
CN110294751B (zh) *	2018-03-21	2020-11-20	湖南化工研究院有限公司	具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用
US12522583B2 (en)	2018-11-07	2026-01-13	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en)	2018-11-07	2022-07-27	Dana-Farber Cancer Institute, Inc.	IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en)	2018-11-07	2022-08-10	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020263830A1 (en)	2019-06-25	2020-12-30	Gilead Sciences, Inc.	Flt3l-fc fusion proteins and methods of use
GB201910608D0 (en) *	2019-07-24	2019-09-04	Enterprise Therapeutics Ltd	Compounds
ES2973832T3 (es)	2019-10-18	2024-06-24	Forty Seven Inc	Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja)	2019-10-31	2022-12-19	フォーティセブン，インコーポレイテッド	抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
CN115151540A (zh) *	2019-12-02	2022-10-04	风暴治疗有限公司	作为mettl3抑制剂的多杂环化合物
IL294032A (en)	2019-12-24	2022-08-01	Carna Biosciences Inc	Compounds that regulate diacylglycerol kinase
US20220402858A1 (en) *	2019-12-26	2022-12-22	Seika Corporation	Method for preparing diaminobiphenyl compound
BR112022014058A2 (pt)	2020-01-20	2022-09-13	Genzyme Corp	Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
TWI890283B (zh)	2020-02-14	2025-07-11	美商基利科學股份有限公司	結合ccr8之抗體及融合蛋白及其用途
IL297327B2 (en)	2020-05-01	2026-01-01	Gilead Sciences Inc	4,2-dioxopyrimidine compounds CD73 inhibitors
US11691963B2 (en)	2020-05-06	2023-07-04	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN114249694B (zh) *	2020-09-22	2025-06-17	浙江四维医药科技有限公司	一种特格拉赞中间体的制备方法
AU2021398051A1 (en)	2020-12-10	2023-07-27	Principia Biopharma Inc.	Crystal form of tolebrutinib, preparation method therefor and use thereof
US12043632B2 (en)	2020-12-23	2024-07-23	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en)	2021-05-18	2022-11-24	Gilead Sciences, Inc.	Methods of using flt3l-fc fusion proteins
MX2023014762A (es)	2021-06-23	2024-01-15	Gilead Sciences Inc	Compuestos moduladores de diacilglicerol quinasa.
AU2022299051B2 (en)	2021-06-23	2025-03-13	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
JP7686091B2 (ja)	2021-06-23	2025-05-30	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
JP7787991B2 (ja)	2021-10-29	2025-12-17	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｄ７３化合物
WO2023086319A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en)	2021-11-09	2024-12-10	Ajax Therapeutics, Inc.	Forms and compositions of inhibitors of JAK2
KR20240123836A (ko)	2021-12-22	2024-08-14	길리애드 사이언시즈, 인코포레이티드	이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en)	2021-12-22	2024-10-22	Gilead Sciences, Inc.	IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
WO2023178181A1 (en)	2022-03-17	2023-09-21	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
KR20240165995A (ko)	2022-03-24	2024-11-25	길리애드 사이언시즈, 인코포레이티드	Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
CR20240451A (es)	2022-04-21	2024-12-04	Gilead Sciences Inc	Compuestos de modulación de kras g12d
KR20250028371A (ko)	2022-07-01	2025-02-28	길리애드 사이언시즈, 인코포레이티드	Cd73 화합물
US20260042743A1 (en) *	2022-08-01	2026-02-12	Council Of Scientific And Industrial Research	Substituted benzimidazoles for treating viral diseases
WO2024064668A1 (en)	2022-09-21	2024-03-28	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en)	2022-12-22	2025-06-05	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
CN116332779B (zh) *	2023-03-13	2025-06-10	苏州敬业医药化工有限公司	一种3,4-二氨基苯甲酸甲酯的制备方法
JPWO2024190888A1 (pt) *	2023-03-16	2024-09-19
AU2024252725A1 (en)	2023-04-11	2025-11-06	Gilead Sciences, Inc.	Kras modulating compounds
CR20250446A (es)	2023-04-21	2025-12-02	Gilead Sciences Inc	Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en)	2023-06-30	2026-01-08	Gilead Sciences, Inc.	Kras modulating compounds
KR20260046403A (ko)	2023-07-26	2026-04-07	길리애드 사이언시즈, 인코포레이티드	Parp7 저해제
CN121620513A (zh)	2023-07-26	2026-03-06	吉利德科学公司	Parp7抑制剂
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250109147A1 (en)	2023-09-08	2025-04-03	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20260098049A1 (en)	2024-08-12	2026-04-09	Gilead Sciences, Inc.	Kras modulating compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3006671A1 (de)	1980-02-22	1981-08-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja)	1989-09-22	1994-01-05	ファイザー製薬株式会社	新規なベンゾイミダゾール化合物
US6608084B1 (en)	1998-08-26	2003-08-19	Aventis Pharma Ltd.	Aza-bicycles which modulate the inhibition of cell adhesion
WO2000049005A1 (en) *	1999-02-16	2000-08-24	Aventis Pharma Limited	Bicyclic compounds and their use as integrin receptor ligands
ES2231179T3 (es) *	1999-04-12	2005-05-16	Aventis Pharma Limited	Compuestos de heteroarilo biciclicos sustituidos como antagonistas de la integrina.
ES2321055T3 (es)	1999-05-05	2009-06-02	Aventis Pharma Limited	Compuestos biblicos sustituidos.
US6340681B1 (en)	1999-07-16	2002-01-22	Pfizer Inc	2-benzimidazolylamine compounds as ORL-1-receptor agonists
CA2384378C (en) *	1999-10-06	2011-05-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
FR2833948B1 (fr)	2001-12-21	2004-02-06	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
AU2003220970A1 (en)	2002-03-01	2003-09-16	Smithkline Beecham Corporation	Diamino-pyrimidines and their use as angiogenesis inhibitors
WO2003082272A1 (en)	2002-03-29	2003-10-09	Chiron Corporation	Substituted benzazoles and use thereof as raf kinase inhibitors
US7037902B2 (en)	2002-07-03	2006-05-02	Receptron, Inc.	Affinity small molecules for the EPO receptor
JP4768265B2 (ja)	2002-10-15	2011-09-07	シンタファーマシューティカルズコーポレーション	新規化合物
JP2006517234A (ja)	2003-02-10	2006-07-20	アムジエン・インコーポレーテツド	バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
FR2851563B1 (fr)	2003-02-26	2005-04-22	Sod Conseils Rech Applic	Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en)	2003-03-21	2009-05-12	Amgen Inc.	Heterocyclic compounds and methods of use
FR2852957B1 (fr) *	2003-03-31	2005-06-10	Sod Conseils Rech Applic	Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en)	2003-04-03	2008-02-12	Ewha University-Industry Collaboration Foundation	Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
EP1677791A4 (en)	2003-10-31	2007-08-15	Takeda Pharmaceutical	NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
AU2005254783A1 (en)	2004-06-18	2005-12-29	Biolipox Ab	Indoles useful in the treatment of inflammation
US7723340B2 (en)	2005-01-13	2010-05-25	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) *	2005-01-13	2009-04-21	Signal Pharmaceuticals, Llc	Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101142185A (zh)	2005-01-19	2008-03-12	比奥里波克斯公司	用于炎症治疗的吲哚
CA2599320A1 (en)	2005-02-25	2006-08-31	Kudos Pharmaceuticals Limited	Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
US20060223849A1 (en) *	2005-03-14	2006-10-05	Mjalli Adnan M	Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
EP1966222A2 (en) *	2005-11-16	2008-09-10	SGX Pharmaceuticals, Inc.	Pyrazolothiazole protein kinase modulators
CN101379060B (zh)	2006-02-10	2012-05-23	转化技术制药公司	作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
US20070287344A1 (en) *	2006-06-12	2007-12-13	Hiroshi Ohara	Fabric Construction Specifically For Damper
WO2008009924A2 (en)	2006-07-18	2008-01-24	Biolipox Ab	Indoles useful in the treatment of inflammation
WO2008035956A1 (en)	2006-09-22	2008-03-27	Ewha University - Industry Collaboration Foundation	New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same
WO2008071944A1 (en)	2006-12-14	2008-06-19	Boehringer Ingelheim International Gmbh	Benzoxazoles useful in the treatment of inflammation
WO2008129276A1 (en)	2007-04-19	2008-10-30	Boehringer Ingelheim International Gmbh	Disulfonamides useful in the treatment of inflammation
UY32138A (es)	2008-09-25	2010-04-30	Boehringer Ingelheim Int	Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es)	2009-03-05	2010-10-29	Boehringer Ingelheim Int	Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8759537B2 (en)	2010-08-20	2014-06-24	Boehringer Ingelheim International Gmbh	3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en)	2010-08-20	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of the microsomal prostaglandin E2 synthase-1
UY33779A (es)	2010-12-10	2012-07-31	Boehringer Ingelheim Int	?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8486968B2 (en) *	2010-12-10	2013-07-16	Boehringer Ingelheim International Gmbh	Compounds
US8466186B2 (en)	2010-12-10	2013-06-18	Boehringer Ingelheim International Gmbh	Compounds

2009
- 2009-09-24 UY UY0001032138A patent/UY32138A/es not_active Application Discontinuation
- 2009-09-25 EP EP09783402A patent/EP2334652A1/en not_active Withdrawn
- 2009-09-25 JP JP2011528330A patent/JP5591807B2/ja not_active Expired - Fee Related
- 2009-09-25 BR BRPI0919292A patent/BRPI0919292A2/pt not_active IP Right Cessation
- 2009-09-25 AU AU2009295814A patent/AU2009295814A1/en not_active Abandoned
- 2009-09-25 US US13/119,836 patent/US8703796B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062425 patent/WO2010034799A1/en not_active Ceased
- 2009-09-25 JP JP2011528332A patent/JP5342646B2/ja not_active Expired - Fee Related
- 2009-09-25 RU RU2011116129/04A patent/RU2011116129A/ru not_active Application Discontinuation
- 2009-09-25 US US13/119,834 patent/US8916599B2/en not_active Expired - Fee Related
- 2009-09-25 CA CA2737384A patent/CA2737384A1/en not_active Abandoned
- 2009-09-25 RU RU2011116128/04A patent/RU2011116128A/ru not_active Application Discontinuation
- 2009-09-25 TW TW098132575A patent/TW201016682A/zh unknown
- 2009-09-25 AU AU2009295816A patent/AU2009295816A1/en not_active Abandoned
- 2009-09-25 BR BRPI0919295A patent/BRPI0919295A2/pt not_active IP Right Cessation
- 2009-09-25 CN CN2009801469428A patent/CN102224143A/zh active Pending
- 2009-09-25 KR KR1020117006845A patent/KR20110056530A/ko not_active Withdrawn
- 2009-09-25 RU RU2011116133/04A patent/RU2011116133A/ru not_active Application Discontinuation
- 2009-09-25 JP JP2011528331A patent/JP5591808B2/ja not_active Expired - Fee Related
- 2009-09-25 WO PCT/EP2009/062422 patent/WO2010034797A1/en not_active Ceased
- 2009-09-25 CN CN2009801371627A patent/CN102164922A/zh active Pending
- 2009-09-25 KR KR1020117006846A patent/KR20110060910A/ko not_active Withdrawn
- 2009-09-25 MX MX2011003094A patent/MX2011003094A/es not_active Application Discontinuation
- 2009-09-25 US US13/119,835 patent/US9040565B2/en not_active Expired - Fee Related
- 2009-09-25 EP EP09783405A patent/EP2361252A1/en not_active Withdrawn
- 2009-09-25 AR ARP090103703A patent/AR073684A1/es unknown
- 2009-09-25 KR KR1020117006974A patent/KR20110065478A/ko not_active Withdrawn
- 2009-09-25 NZ NZ591846A patent/NZ591846A/xx not_active IP Right Cessation
- 2009-09-25 CN CN2009801376014A patent/CN102164924A/zh active Pending
- 2009-09-25 TW TW098132579A patent/TW201016696A/zh unknown
- 2009-09-25 CN CN2009801376052A patent/CN102164911A/zh active Pending
- 2009-09-25 MX MX2011002948A patent/MX2011002948A/es active IP Right Grant
- 2009-09-25 NZ NZ591845A patent/NZ591845A/xx not_active IP Right Cessation
- 2009-09-25 MX MX2011002903A patent/MX2011002903A/es active IP Right Grant
- 2009-09-25 TW TW098132581A patent/TW201018684A/zh unknown
- 2009-09-25 BR BRPI0919738A patent/BRPI0919738A2/pt not_active IP Right Cessation
- 2009-09-25 CA CA2737552A patent/CA2737552A1/en not_active Abandoned
- 2009-09-25 EP EP09783403A patent/EP2334664A1/en not_active Withdrawn
- 2009-09-25 AR ARP090103704A patent/AR073685A1/es unknown
- 2009-09-25 TW TW098132551A patent/TW201018669A/zh unknown
- 2009-09-25 RU RU2011116131/04A patent/RU2011116131A/ru not_active Application Discontinuation
- 2009-09-25 JP JP2011528333A patent/JP5342647B2/ja not_active Expired - Fee Related
- 2009-09-25 MX MX2011003152A patent/MX2011003152A/es active IP Right Grant
- 2009-09-25 AU AU2009295815A patent/AU2009295815A1/en not_active Abandoned
- 2009-09-25 AR ARP090103706A patent/AR073403A1/es unknown
- 2009-09-25 KR KR1020117006971A patent/KR20110056533A/ko not_active Withdrawn
- 2009-09-25 WO PCT/EP2009/062421 patent/WO2010034796A1/en not_active Ceased
- 2009-09-25 EP EP09783406.3A patent/EP2350073B1/en not_active Not-in-force
- 2009-09-25 AU AU2009295813A patent/AU2009295813A1/en not_active Abandoned
- 2009-09-25 CA CA2737839A patent/CA2737839A1/en not_active Abandoned
- 2009-09-25 US US13/119,832 patent/US8598190B2/en not_active Expired - Fee Related
- 2009-09-25 AR ARP090103705A patent/AR073686A1/es unknown
- 2009-09-25 NZ NZ591843A patent/NZ591843A/xx not_active IP Right Cessation
- 2009-09-25 NZ NZ591847A patent/NZ591847A/xx not_active IP Right Cessation
- 2009-09-25 WO PCT/EP2009/062424 patent/WO2010034798A1/en not_active Ceased
- 2009-09-25 CA CA2738083A patent/CA2738083A1/en not_active Abandoned
2011
- 2011-02-09 IL IL211137A patent/IL211137A0/en unknown
- 2011-02-09 ZA ZA2011/01041A patent/ZA201101041B/en unknown
- 2011-02-09 IL IL211138A patent/IL211138A0/en unknown
- 2011-02-09 ZA ZA2011/01042A patent/ZA201101042B/en unknown
- 2011-02-10 IL IL211147A patent/IL211147A0/en unknown
- 2011-02-10 IL IL211148A patent/IL211148A0/en unknown

Also Published As

Publication number	Publication date
US8703796B2 (en)	2014-04-22
WO2010034797A1 (en)	2010-04-01
CA2737384A1 (en)	2010-04-01
IL211137A0 (en)	2011-04-28
RU2011116133A (ru)	2012-10-27
JP5591808B2 (ja)	2014-09-17
NZ591843A (en)	2012-09-28
EP2350073B1 (en)	2014-11-12
UY32138A (es)	2010-04-30
AU2009295816A1 (en)	2010-04-01
MX2011003094A (es)	2011-04-26
ZA201101042B (en)	2011-10-26
EP2334652A1 (en)	2011-06-22
AR073686A1 (es)	2010-11-24
IL211148A0 (en)	2011-04-28
KR20110056533A (ko)	2011-05-30
TW201018669A (en)	2010-05-16
WO2010034796A1 (en)	2010-04-01
ZA201101041B (en)	2011-10-26
MX2011003152A (es)	2011-04-27
US20110275656A1 (en)	2011-11-10
CN102164922A (zh)	2011-08-24
CN102224143A (zh)	2011-10-19
TW201016696A (en)	2010-05-01
US20120115902A1 (en)	2012-05-10
JP2012503629A (ja)	2012-02-09
EP2361252A1 (en)	2011-08-31
CN102164924A (zh)	2011-08-24
AR073685A1 (es)	2010-11-24
WO2010034799A1 (en)	2010-04-01
US8598190B2 (en)	2013-12-03
US20110312935A1 (en)	2011-12-22
BRPI0919295A2 (pt)	2015-12-15
EP2334664A1 (en)	2011-06-22
US9040565B2 (en)	2015-05-26
AU2009295814A1 (en)	2010-04-01
US8916599B2 (en)	2014-12-23
AU2009295813A1 (en)	2010-04-01
JP2012503628A (ja)	2012-02-09
RU2011116128A (ru)	2012-10-27
EP2350073A1 (en)	2011-08-03
MX2011002948A (es)	2011-04-26
TW201018684A (en)	2010-05-16
AU2009295815A1 (en)	2010-04-01
TW201016682A (en)	2010-05-01
JP5342647B2 (ja)	2013-11-13
JP2012503627A (ja)	2012-02-09
CA2737552A1 (en)	2010-04-01
WO2010034798A1 (en)	2010-04-01
RU2011116131A (ru)	2012-10-27
IL211138A0 (en)	2011-04-28
JP2012503630A (ja)	2012-02-09
JP5591807B2 (ja)	2014-09-17
KR20110065478A (ko)	2011-06-15
CA2738083A1 (en)	2010-04-01
RU2011116129A (ru)	2012-10-27
NZ591847A (en)	2013-01-25
MX2011002903A (es)	2011-04-11
NZ591845A (en)	2012-10-26
NZ591846A (en)	2012-11-30
CA2737839A1 (en)	2010-04-01
AR073403A1 (es)	2010-11-03
JP5342646B2 (ja)	2013-11-13
KR20110056530A (ko)	2011-05-30
IL211147A0 (en)	2011-04-28
CN102164911A (zh)	2011-08-24
US20120122930A1 (en)	2012-05-17
AR073684A1 (es)	2010-11-24
BRPI0919738A2 (pt)	2015-12-08
KR20110060910A (ko)	2011-06-08

Legal Events

Date	Code	Title	Description
2017-06-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Publication	Publication Date	Title
BRPI0919292A2 (pt)	2017-05-30	3h-imidazo[4,5-b] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI1009118A2 (pt)	2016-12-06	3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
BRPI0919948A2 (pt)	2015-08-25	Pirido[4,3-b]indois contendo porções rígidas
SMT201400123B (it)	2014-11-10	Imidazo[1,2B]piridazine sostituite come inibitori di trk-chinasi
BRPI1008899A2 (pt)	2018-03-13	derivados 3,3´-espiroindolinona como agentes anticâncer
BRPI0914657A2 (pt)	2019-09-24	piridin-2-onae piridazin-3-onas substituídas
ZA201002013B (en)	2010-11-24	BICYCLIC y-AMINO ACID DERIVATIVES
BRPI1014956A2 (pt)	2018-07-24	agentes antinflamatórios.
BRPI0810462A2 (pt)	2014-10-14	Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0812411A2 (pt)	2014-12-02	Amidas de ácido pirazol carboxílico úteis como microbicidas
BRPI0817562A2 (pt)	2017-05-02	derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
PL2294086T3 (pl)	2018-02-28	Środki przeciwzapalne
BRPI0914301A2 (pt)	2015-10-13	derivados de pirimidin-4-ona substituída
FI20086158A0 (fi)	2008-12-03	Imidatsopyridiinijohdannaiset
BRPI0914665A2 (pt)	2015-10-20	derivados de pirimido[2,1-a]isoquinolin-4-ona substituída
EP2142542A4 (en)	2011-06-22	NEW IMIDAZO [4,5-B] PYRIDINE-7-CARBOXYLAMIDEAMIDE 704
BRPI0915417A2 (pt)	2015-11-03	derivados de 3-(3-pirimidin-2-il-benzil)-[1,2,4]triazolo [4,3-b]piridazina como inibidores da met quinase
IL229993A (en)	2015-10-29	8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
DK2356123T3 (da)	2012-10-15	Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulener
ZA201208616B (en)	2015-08-26	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
EP2443124A4 (en)	2012-11-21	SUBSTITUTED 1,3,8-TRIAZASPIRO- [4.5-] DECANE-2,4-DIONE
BRPI0811924A2 (pt)	2014-11-25	Derivados de butona úteis como agentes refrigerantes
EP2511276A4 (en)	2012-12-19	Pyrrolo [2,3-D] pyrimidine derivative
BRPI0812912A2 (pt)	2014-12-09	Derivados de pirrol como antagonistas de p2y12
BRPI1012581A2 (pt)	2016-03-29	derivados de amidas de ácido 6, 7-di-hidro-5h-imidazol[1,2-a]imidazol-3-carboxílico